Announcements Trials

Browse Landscape

Phase

Phase 2 5 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Breast Neoplasms 5 Leukemia 4 Recurrence 3 Leukemia, Myeloid, Acute 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lung Neoplasms 2 Leukemia, Myeloid, Chronic-Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Glioblastoma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Wilms Tumor 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Teratoma 1 Spinal Cord Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma, Embryonal 1 Rhabdomyosarcoma, Alveolar 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Ovarian Germ Cell Cancer 1 Osteosarcoma 1 Optic Nerve Glioma 1

Interventions

pembrolizumab 74 Nivolumab 53 Ipilimumab 42 Cyclophosphamide 32 Interleukin-2 24 aldesleukin 23 Temozolomide 17 fludarabine 16 Biopsy 11 trametinib 10 fludarabine phosphate 10 dabrafenib 10 spartalizumab 8 Paclitaxel 8 Dacarbazine 8 sargramostim 7 cemiplimab 7 binimetinib 7 Cisplatin 7 Bevacizumab 7 poly ICLC 6 lenvatinib 6 epacadostat 6 Radiotherapy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5 encorafenib 5 atezolizumab 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × Dasatinib × Clear all

NCT00597038 2013-12-16

A Phase I/II Study of Dasatinib and Dacarbazine

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed

50 enrolled 11 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡